-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on September 3, the CDE official website showed that the marketing application for Roche (RHHBY.US) vamicibimab injection was accepted for the treatment of uveal inflammatory macular edema (UME). Previously, the application had been included by the CDE in the priority review and approval process.

Zhitongcaijing·09/04/2026 07:25:07
Listen to the news
The Zhitong Finance App learned that on September 3, the CDE official website showed that the marketing application for Roche (RHHBY.US) vamicibimab injection was accepted for the treatment of uveal inflammatory macular edema (UME). Previously, the application had been included by the CDE in the priority review and approval process.